In an unusual and unexpected twist, the U.S. Department of Justice (DOJ) filed an “unopposed motion … to dismiss with prejudice” a June 2024 criminal indictment against a Cassava Sciences advisor after he and the clinical-stage biopharmaceutical company became the target of an apparent short-selling scheme that prompted government investigations.
